140 related articles for article (PubMed ID: 9566470)
1. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
Moore RD; Chaisson RE
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
Rose DN; Sacks HS
AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
[TBL] [Abstract][Full Text] [Related]
5. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.
Paltiel AD; Goldie SJ; Losina E; Weinstein MC; Seage GR; Kimmel AD; Zhang H; Freedberg KA
Clin Infect Dis; 2001 Mar; 32(5):783-93. PubMed ID: 11229847
[TBL] [Abstract][Full Text] [Related]
6. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
[TBL] [Abstract][Full Text] [Related]
7. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.
Teerawattananon K; Iewsakul S; Yenjitr C; Ausayakhun S; Yenjitr W; Mugford M; Teerawattananon Y
Pharmacoeconomics; 2007; 25(5):413-28. PubMed ID: 17488139
[TBL] [Abstract][Full Text] [Related]
9. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease.
Liu GG; Hay J
Pharm Res; 2000 Aug; 17(8):911-9. PubMed ID: 11028934
[TBL] [Abstract][Full Text] [Related]
10. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.
Kempen JH; Frick KD; Jabs DA
Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
12. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
14. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making.
Annemans L; Moeremans K; Mutimer D; Schneeberger H; Milligan D; Kubin M
Value Health; 2002; 5(4):347-58. PubMed ID: 12102697
[TBL] [Abstract][Full Text] [Related]
15. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
16. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
Puttarajappa CM; Hariharan S; Smith KJ
Clin J Am Soc Nephrol; 2018 Feb; 13(2):290-298. PubMed ID: 29025787
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
18. Oral ganciclovir.
Schouten JT
STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
[TBL] [Abstract][Full Text] [Related]
19. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
Luan FL; Kommareddi M; Ojo AO
Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
[TBL] [Abstract][Full Text] [Related]
20. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
Spector SA; McKinley GF; Lalezari JP; Samo T; Andruczk R; Follansbee S; Sparti PD; Havlir DV; Simpson G; Buhles W; Wong R; Stempien M
N Engl J Med; 1996 Jun; 334(23):1491-7. PubMed ID: 8618603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
